Phase I study evaluating safety, pharmacokinetics (PK), pharmacodynamics, and preliminary efficacy of ABBV-428, first-in-class mesothelin (MSLN)-CD40 bispecific, in patients (pts) with advanced solid tumours
Version 2 2024-06-19, 00:50Version 2 2024-06-19, 00:50
Version 1 2021-01-12, 14:30Version 1 2021-01-12, 14:30
conference contribution
posted on 2024-06-19, 00:50authored byJJ Luke, L Fong, K Chung, AW Tolcher, K Kelly, A Hollebecque, C Le Tourneau, V Subbiah, F Tsai, S Kao, P Cassier, M Khasraw, K Allaire, F Fan, H Fang, M Patel, W Henner, J Hayflick, M McDevitt, F Barlesi
Phase I study evaluating safety, pharmacokinetics (PK), pharmacodynamics, and preliminary efficacy of ABBV-428, first-in-class mesothelin (MSLN)-CD40 bispecific, in patients (pts) with advanced solid tumours